---
title: Osimertinib after Chemoradiotherapy in Stage III <em>EGFR</em>-Mutated NSCLC
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38828946/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240603181443&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Treatment with osimertinib resulted in significantly longer
  progression-free survival than placebo in patients with unresectable stage III EGFR-mutated
  NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Treatment with osimertinib resulted in significantly longer progression-free survival than placebo in patients with unresectable stage III EGFR-mutated NSCLC. (Funded by AstraZeneca; LAURA ClinicalTrials.gov number, ...